Universite Claude Bernard – Lyon1

Centre National De La Recherche Scientifique

Hospices Civils De Lyon

Institut National De La Sante Et De La Recherche Medicale

Universitè Laval

Ecole Normale Superieure De Lyon

Centre National De La Recherche Scientifique-Cnrs

Institut National De La Sante Et De La Recherche Medicale (Inserm)

University of Dundee

Université Claude Bernard Lyon I

Calixar

Université Claud Bernard Lyon 1

Manuel Rosa-Calatrava

Olivier Terrier

Guy Boivin

Julien Textoris

Vincent Moules

Mario Andres Pizzorno

Jean-Christophe Bourdon

Jean-Jacques Diaz

Olivier Ferraris

Marie-Helene Cavanagh

Anaïs Proust

Claire Nicolas De Lamballerie

Marie-Eve Hamelin

Emmanuel Dejean

Mario Pizzorno

Mario-Andres Pizzorno

Laurence Josset

Blandine Padey

Aurélien Traversier

Matthieu Yver

Élodie Desuzinges-Mandon

Julia Dubois

The invention relates to a combination of Diltiazem and at least one viral polymerase inhibitor compound selected from among Baloxavir marboxil, Pimodivir, RO-7 and CC-42344. The invention relates in particular to the therapeutic use of said combination in the prevention and/or treatment of a viral infection, in particular of the respiratory and/or intestinal tract of a human or animal body.

Combination of diltiazem and viral polymerase inhibitors

The present invention relates to diltiazem for use as an agent for activating the expression of at least one gene encoding a type III interferon, in the prevention and/or treatment of infections by at least one pathogenic microorganism of the epithelia of the respiratory and/or intestinal tracts.

Diltiazem for use in the treatment of microbial infections

The present invention relates to a pharmaceutical or veterinary composition for its use in preventing and/or treating a MERS-CoV (Middle-East Respiratory Syndrome) coronavirus infection, characterised in that it comprises, in a suitable pharmaceutical vehicle, at least one compound chosen from apigenin and berberine.

Antiviral compositions for the treatment of infections linked to coronaviruses

The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain comprising one or more genetic modifications of said sequence SEQ ID NO. 1 attenuating the virulence of said strain.

Attenuated virus strain and use thereof as a vaccine

The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. Said composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.

Antiviral compositions for treating the flu

The present invention relates to a method for preparing a vaccine antigen, which includes a step of fragmenting a biological membrane associated with said vaccine antigen by treating said biological membrane with at least one calixarene of formula (II): wherein: X is a &#x2014;(CH2)-CO2Y group and Y is an alkaline metal or one of the pharmaceutically acceptable salts thereof, wherein said resulting vaccine antigen also includes a fragment of the biological membrane associated with said antigen. The present invention also relates to a vaccine that can be produced by implementing the method, including a calixarene of formula (II) in carrier format, with a quantity of 0.1 to 1,000 &#x3bc;g in the total weight of the vaccine. The present invention further relates to the use of a calixarene as defined above for the preparation of a vaccine or a vaccine antigen, and to the vaccine for use as a drug in the treatment or prevention of an infectious disease. 

Method for preparing a vaccine antigen, resulting vaccine antigen and uses

Pharmaceutical or veterinary compositions to prevent or treat viral infections, in particular to prevent or treat influenza A, B and C virus infections.

Pharmaceutical or veterinary antiviral compositions

The present invention relates to a method for improving the production of an influenza virus, and in particular influenza vaccine seeds, or a vaccine directed against an influenza virus, characterized in that the production is carried out in the presence of an inhibitor of the interaction between the Mdm2 protein and the p53 protein.

Method for improving the production of influenza viruses and vaccine seeds

Modified influenza A/PR/8/34 virus and reassortant influenza A/PR/8/34 virus including a modified PB1 gene and methods for improving the production of HA (hemagglutinin) and NA (neuraminidase) vaccine glycoproteins.

Modified viral strains and method for improving the production of vaccine seeds of influenza virus

Growing community of inventors

Lyons, France

Manuel Rosa-Calatrava